Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu... (t(R) appeared to provide a similar magni...)

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

Date:12/8/2008

t(R) appeared to provide a similar magnitude of seizure reduction versus placebo regardless of which AED was included as part of the patients' baseline treatment regimen, which included one to three concomitant AEDs:

    -- Carbamazepine (36.5 percent seizure frequency reduction with Vimpat(R)
       400 mg/day vs. 21.7 percent with placebo)
    -- Lamotrigine (33.3 percent vs. 18.3 percent)
    -- Levetiracetam (37.6 percent vs. 17.6 percent)
    -- Valproate (45.3 percent vs. 21.3 percent)
    -- Topiramate (41.4 percent vs. 28.5 percent)
    -- Oxcarbazepine (27.2 percent vs. 12.5 percent)

Similar results were seen for responder rates (patients with 50 percent or greater reduction in seizure frequency):

    -- Carbamazepine (37.4 percent responder rate with Vimpat(R) 400 mg/day
       vs. 26.4 percent placebo)
    -- Lamotrigine (34.2 percent vs. 19.0 percent)
    -- Levetiracetam (43.4 percent vs. 19.4 percent)
    -- Valproate (47.5 percent vs. 26.9 percent)
    -- Topiramate (41.9 percent vs. 25.6 percent)
    -- Oxcarbazepine (29.7 percent vs. 17.6 percent)

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.246)

William Rosenfeld, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty, PhD

The Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, Missouri

Schwarz Biosciences Inc. (a member of the UCB Group), Raleigh, NC, USA

Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials

This pooled analysis clinical trial safety data showed Vimpat(R) to be generally well-tolerated, although 85 percent of trial participants were already taking two to three concomitant AEDs upon trial entry:

-- The most frequently reported individual treatment emergent adverse events (TEAE) occurring in greater than or equal to 10 percent of the Vimpat(
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers

Post Your Comments:

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu...(t(R) appeared to provide a similar magni...)